CommBank
CBA
ANZ Group Holdings Ltd
ANZ
Westpac Banking Corp
WBC
National Australia Bank Ltd
NAB
Fortescue Ltd
FMG
AU Stock MarketDetailed Quotes
PARO Paradigm Biopharmaceuticals Ltd
- 0.004
- 0.0000.00%
20min DelayTrading Nov 25 16:00 AET
1.40MMarket Cap0.00P/E (Static)
0.000High0.000Low0Volume0.000Open0.004Pre Close0.00Turnover0.10052wk High0.00%Turnover Ratio349.43MShares0.00152wk Low--EPS TTM1.22MFloat Cap0.100Historical High0.00P/E (Static)305.06MShs Float0.001Historical Low--EPS LYR0.00%Amplitude--Dividend TTM0.00P/B1Lot Size--Div YieldTTM
Paradigm Biopharmaceuticals Ltd Key Stats
Quarterly+Annual
YOY
| (FY)Jun 30, 2024 | (FY)Jun 30, 2023 | (FY)Jun 30, 2022 | (FY)Jun 30, 2021 | (FY)Jun 30, 2020 | (FY)Jun 30, 2019 | |
|---|---|---|---|---|---|---|
| Operating cash flow (direct method) | ||||||
| Cash income from operating activities | -0.24%7.41M | -22.68%7.43M | 185.03%9.61M | -6.93%3.37M | 56.18%3.62M | 2.32M |
| Revenue from customers | 259.76%82.9K | -71.71%23.04K | --81.44K | ---- | ---- | ---- |
| Other cash income from operating activities | -1.05%7.33M | -22.26%7.4M | 182.62%9.53M | -6.93%3.37M | 56.18%3.62M | --2.32M |
| Cash paid | -38.54%-74.19M | -28.01%-53.55M | -8.59%-41.83M | -160.33%-38.52M | -68.67%-14.8M | -8.77M |
| Payments to suppliers for goods and services | -38.54%-74.19M | -28.01%-53.55M | -8.59%-41.83M | -160.33%-38.52M | -68.67%-14.8M | ---8.77M |
| Direct interest paid | 12.46%-14.37K | 42.67%-16.42K | 24.09%-28.63K | -10.40%-37.72K | ---34.17K | ---- |
| Direct interest received | -11.00%845.9K | 1,882.92%950.46K | -81.56%47.93K | -76.79%259.96K | 1,154.96%1.12M | --89.26K |
| Operating cash flow | -45.94%-65.94M | -40.31%-45.19M | 7.80%-32.21M | -246.18%-34.93M | -58.52%-10.09M | ---6.37M |
| Investing cash flow | ||||||
| Cash flow from continuing investing activities | -88.11%668.37K | 186.21%5.62M | -6.52M | |||
| Net PPE purchase and sale | ---- | ---- | ---- | 75.86%-30.78K | -617.27%-127.54K | ---17.78K |
| Net intangibles purchas and sale | ---- | ---- | ---- | 74.65%-850 | 20.13%-3.35K | ---4.2K |
| Net investment purchase and sale | ---- | ---- | ---- | -87.83%700K | 188.52%5.75M | ---6.5M |
| Cash from discontinued investing activities | ||||||
| Investing cash flow | ---- | ---- | ---- | -88.11%668.37K | 186.21%5.62M | ---6.52M |
| Financing cash flow | ||||||
| Cash flow from continuing financing activities | -54.94%28.18M | 89,087.38%62.53M | -93.01%70.12K | -97.22%1M | -56.45%36.05M | 82.78M |
| Net issuance payments of debt | ---- | 102.81%416.34K | 98.01%205.29K | -94.53%103.68K | --1.9M | ---- |
| Net common stock issuance | -54.55%28.28M | --62.22M | ---- | -97.02%1.02M | -58.62%34.25M | --82.78M |
| Net other financing activities | 2.06%-102.34K | 22.70%-104.49K | -10.93%-135.17K | -30.22%-121.85K | ---93.57K | ---- |
| Cash from discontinued financing activities | ||||||
| Financing cash flow | -54.94%28.18M | 89,087.38%62.53M | -93.01%70.12K | -97.22%1M | -56.45%36.05M | --82.78M |
| Net cash flow | ||||||
| Beginning cash position | 41.99%56.33M | -44.15%39.67M | -31.65%71.03M | 43.67%103.92M | 2,857.77%72.34M | --2.45M |
| Current changes in cash | -317.70%-37.77M | 153.99%17.35M | 3.38%-32.14M | -205.30%-33.26M | -54.81%31.59M | --69.89M |
| Effect of exchange rate changes | -7.96%-744.54K | -189.04%-689.67K | 108.61%774.58K | --371.3K | ---- | ---- |
| End cash Position | -68.37%17.82M | 41.99%56.33M | -44.15%39.67M | -31.65%71.03M | 43.67%103.92M | --72.34M |
| Free cash from | -45.94%-65.94M | -40.31%-45.19M | 7.88%-32.21M | -242.05%-34.96M | -60.03%-10.22M | ---6.39M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |